Cardiovascular disease (CVD) is the leading cause of death in the United States, accounting for one out of every three to four deaths. CVDs comprise the major disorders of the heart and arterial circulation supplying the heart, brain, and peripheral tissue. The epidemiology of CVD, coronary heart disease, and stroke largely involves the identification and investigation of risk factors that contribute to increasing or decreasing the risk of this major public health burden of disease.

Long-Chain Omega-3 Fatty Acids Eicosapentaenoic Acid and Docosahexaenoic Acid and Blood Pressure: A Meta-Analysis of Randomized Controlled Trials

Although a large body of literature has been devoted to examining the relationship between eicosapentaenoic and docosahexaenoic acids (EPA+DHA) and blood pressure, past systematic reviews have been hampered by narrow inclusion criteria and a limited scope of analytical subgroups. In addition, no meta-analysis to date has captured the substantial volume of randomized controlled trials (RCTs) published in the past 2 years. The objective of this meta-analysis was to examine the effect of EPA+DHA, without upper dose limits and including food sources, on blood pressure in RCTs. Random-effects meta-analyses were used to generate weighted group mean differences and 95% confidence intervals (CIs) between the EPA+DHA group and the placebo group. Analyses were conducted for subgroups defined by key subject or study characteristics. Seventy RCTs were included. Compared with placebo, EPA+DHA provision reduced systolic blood pressure (-1.52mm Hg; 95% confidence interval (CI) = -2.25 to -0.79) and diastolic blood pressure (- 0.99mmHg; 95% CI = – 1.54 to – 0.44) in the meta-analyses of all studies combined. The strongest effects of EPA+DHA were observed among untreated hypertensive subjects (systolic blood pressure = – 4.51mm Hg, 95% CI = – 6.12 to – 2.83; diastolic blood pressure = – 3.05mm Hg, 95% CI […]

Read Article →